Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
1
Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for azithromycin (systemic use formulations), the scientific conclusions are as follows: In view of the increasing understanding on drug-drug interactions, and more specifically available data from the literature and spontaneous reports, on interaction between azithromycin (systemic use formulations) and colchicine leading to possible increase of colchicine serum level, the PRAC considers that colchicine should be added as example of P-glycoprotein substrates in the existing warning of their possible increased serum levels in case of co-administration with azithromycin. The CMDh agrees with the scientific conclusions made by the PRAC.
Grounds for the variation to the terms of the Marketing Authorisation(s) On the basis of the scientific conclusions for azithromycin (systemic use formulations) the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing azithromycin (systemic use formulations) is unchanged subject to the proposed changes to the product information. The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing azithromycin (systemic use formulations)are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.
2
Annex II Amendments to the product information of the nationally authorised medicinal product(s)
3
Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through) Summary of Product Characteristics •
Section 4.5 Interaction with other medicinal products and other forms of interaction
[A warning should be revised as follows] Digoxin and colchicine: concomitant administration of macrolide antibiotics, including azithromycin, with P-glycoprotein substrates such as digoxin and colchicine, has been reported to result in increased serum levels of the P-glycoprotein substrate. Therefore, if azithromycin and P-glycoprotein substrates such as digoxin are administered concomitantly, the possibility of elevated serum digoxin concentrations should be considered. Clinical monitoring, and possibly serum digoxin levels, during treatment with azithromycin and after its discontinuation are necessary.
Package Leaflet •
Section 2. What you need to know before you take
[A warning should be revised as follows] Other medicines and Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines: […] - Digoxin (used for treatment of cardiac impairment) - Colchicine (used for gout and familial Mediterranean fever)
4
Annex III Timetable for the implementation of this position
5
Timetable for the implementation of this position
Adoption of CMDh position:
January 2018 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:
10 March 2018
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):
Active substance: Azithromycin: CMDh scientific conclusions and ...
Mar 10, 2018 - Scientific conclusions. Taking into account the PRAC Assessment Report on the PSUR(s) for azithromycin (systemic use formulations), the scientific conclusions are as follows: In view of the increasing understanding on drug-drug interactions, and more specifically available data from the literature and ...
Dec 23, 2017 - 2. Scientific conclusions. Taking into account the PRAC Assessment Report on the PSUR(s) for mefloquine, the scientific conclusions are as follows: ... Amendments to be included in the relevant sections of the Product Information (new
Oct 28, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for levobunolol (ophthalmic indication), the scientific conclusions are as ...
Sep 2, 2017 - Summary of Product Characteristics. â¢. Section 4.8. The following adverse reactions should be added under the SOC âReproductive system and ...
Oct 28, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for levobunolol (ophthalmic indication), the ... reactions should be included in the product information for levobunolol-containing products authorised ... indication) is un
PASS to evaluate the effectiveness of the risk minimisation activities as imposed during ... Grounds for the variation to the terms of the Marketing Authorisation(s).
5 days ago - with the frequency not known. The Package Leaflet should be updated accordingly. The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s). On the basis of
The joint database drug utilisation final study report submitted by the MAHs, together with the ... The MAH(s) should provide within the risk management plan.
Oct 29, 2016 - PRAC reviewed the available post marketing safety data, published ... The CMDh reaches the position that the marketing authorisation(s) of ...
Nov 25, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for saccharomyces boulardii, the scientific ... patients is considered changed and an update of the product information is warranted. ... relevant sections of the SmPC (sect
Jul 1, 2017 - ... Report on the PSUR(s) for cetirizine / pseudoephedrine e, ... Grounds for the variation to the terms of the Marketing ... [The following adverse reaction should be added under the SOC Reproductive system and breast.
Apr 7, 2018 - **Uterine rupture has been uncommonly reported after prostaglandin intake during the second or third trimester of pregnancy. Uterine ruptures occurred particularly in multiparous women or in women with a caesarean section scar. Package
Dec 22, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for granisetron ... Annex III. Timetable for the implementation of this position ...
Jun 9, 2018 - Based on a comprehensive review of âparaesthesiaâ, including ... of hypersensitivity reactions to chrysanthemums including literature ...
Aug 5, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... for the variation to the terms of the Marketing Authorisation(s) ... Page 3 ...
Jun 9, 2018 - peak toxicity and prolonged recovery when compared to immediate-release (IR) quetiapine overdose: a retrospective cohort study. Clinical ...
Jun 4, 2017 - Grounds for the variation to the terms of the Marketing Authorisation(s). On the basis of the scientific conclusions for finasteride the CMDh is of ...
Mar 10, 2018 - trace residue from the manufacturing process), or to any of the excipients., or The the stopper of the glass vial with Actilyse powder which contains natural rubber (a derivative of latex). which may cause allergic reactions. No sustai
Dec 27, 2017 - for anxiety in one case and taking into account the listedness of these adverse reactions in the product information of other progestin only medicinal products, the lead member state considers that anxiety and depression should be incl
Aug 5, 2017 - colitis for proton pump inhibitors is relatively small and the number of ... Given the cases with positive de-challenge which clearly support the ...
Nov 25, 2017 - Allergic reactions the signs of which may include difficulty in breathing, dizziness, collapsing or losing consciousness, swelling of your face, lips ...
possible risks with exposure to non-steroidal anti-inflammatory drugs like diclofenac in pregnant women, in ... drugs with regard to use during pregnancy and risk of miscarriage and congenital malformations as agreed ... Women of childbearing potenti
27 Jan 2018 - Taking into account the PRAC Assessment Report on the PSUR(s) for lanthanum, the scientific ... this PSUR, the PRAC considers that the product information of lanthanum containing medicinal products should be ... Amendments to the produc